Monopar Therapeutics shares are trading higher by 108% Thursday morning. The company announced early Phase 1 trial data confirming MNPR-101-Zr's tumor-targeting ability in humans. Get a Year of Fast, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback